EUROFINS SCIENTIFICEUROFINS SCIENTIFICEUROFINS SCIENTIFIC

EUROFINS SCIENTIFIC

No trades
See on Supercharts
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪9.06 B‬EUR
1.98EUR
‪310.30 M‬EUR
‪6.51 B‬EUR
‪127.80 M‬
Beta (1Y)
1.04
Employees (FY)
‪61.8 K‬
Change (1Y)
+419 +0.68%
Revenue / Employee (1Y)
‪116.35 K‬EUR
Net income / Employee (1Y)
‪5.54 K‬EUR

About EUROFINS SCIENT.


CEO
Gilles G. Martin
Headquarters
Luxembourg
Founded
2012
ISIN
FR0014000MR3
FIGI
BBG00L31KTX5
Eurofins Scientific SE engages in the bio-analytical testing of food, environment, and pharmaceuticals products. The firm offers testing and laboratory services for agro science, genomics, discovery pharmacology and for supporting clinical studies. It operates through the following geographical segments: Europe, North America, and Rest of the World. The company was founded by Gilles G. Martin in 1987 and is headquartered in Luxembourg.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
XS234311468
EUROFIN.SCIF 21/31
Yield to maturity
4.35%
Maturity date
May 19, 2031
XS267688311
EUROFIN.SCIF 23/30
Yield to maturity
4.01%
Maturity date
Sep 6, 2030
XS249166413
EUROFIN.SCIF 22/29
Yield to maturity
3.80%
Maturity date
Jul 6, 2029
XS216759567
EUROFIN.SCIF 20/26
Yield to maturity
3.49%
Maturity date
Jul 17, 2026
XS257948030
EUROFIN.SCIF 23/UND. FLR
Yield to maturity
Maturity date
XS171694558
EUROF.SCIENTIF.17/UND.FLR
Yield to maturity
Maturity date

Explore more bonds 

Frequently Asked Questions


The current price of 4ERF is 47.06 EUR — it has increased by 1.23% in the past 24 hours. Watch EUROFINS SCIENTIFIC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on EUROTLX exchange EUROFINS SCIENTIFIC stocks are traded under the ticker 4ERF.
4ERF stock has risen by 3.93% compared to the previous week, the month change is a −0.36% fall, over the last year EUROFINS SCIENTIFIC has showed a −10.69% decrease.
We've gathered analysts' opinions on EUROFINS SCIENTIFIC future price: according to them, 4ERF price has a max estimate of 89.00 EUR and a min estimate of 42.00 EUR. Watch 4ERF chart and read a more detailed EUROFINS SCIENTIFIC stock forecast: see what analysts think of EUROFINS SCIENTIFIC and suggest that you do with its stocks.
4ERF reached its all-time high on Nov 30, 2021 with the price of 113.90 EUR, and its all-time low was 43.94 EUR and was reached on Jun 24, 2024. View more price dynamics on 4ERF chart.
See other stocks reaching their highest and lowest prices.
4ERF stock is 1.21% volatile and has beta coefficient of 1.04. Track EUROFINS SCIENTIFIC stock price on the chart and check out the list of the most volatile stocks — is EUROFINS SCIENTIFIC there?
Today EUROFINS SCIENTIFIC has the market capitalization of ‪8.99 B‬, it has increased by 2.02% over the last week.
Yes, you can track EUROFINS SCIENTIFIC financials in yearly and quarterly reports right on TradingView.
EUROFINS SCIENTIFIC is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
4ERF earnings for the last half-year are 1.64 EUR per share, whereas the estimation was 1.48 EUR, resulting in a 10.77% surprise. The estimated earnings for the next half-year are 1.56 EUR per share. See more details about EUROFINS SCIENTIFIC earnings.
EUROFINS SCIENTIFIC revenue for the last half-year amounts to ‪3.42 B‬ EUR, despite the estimated figure of ‪3.47 B‬ EUR. In the next half-year revenue is expected to reach ‪3.60 B‬ EUR.
4ERF net income for the last half-year is ‪220.70 M‬ EUR, while the previous report showed ‪158.80 M‬ EUR of net income which accounts for 38.98% change. Track more EUROFINS SCIENTIFIC financial stats to get the full picture.
Yes, 4ERF dividends are paid annually. The last dividend per share was 0.50 EUR. As of today, Dividend Yield (TTM)% is 1.06%. Tracking EUROFINS SCIENTIFIC dividends might help you take more informed decisions.
EUROFINS SCIENTIFIC dividend yield was 0.85% in 2023, and payout ratio reached 31.09%. The year before the numbers were 1.49% and 31.55% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Nov 24, 2024, the company has ‪61.80 K‬ employees. See our rating of the largest employees — is EUROFINS SCIENTIFIC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. EUROFINS SCIENTIFIC EBITDA is ‪1.34 B‬ EUR, and current EBITDA margin is 18.59%. See more stats in EUROFINS SCIENTIFIC financial statements.
Like other stocks, 4ERF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade EUROFINS SCIENTIFIC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So EUROFINS SCIENTIFIC technincal analysis shows the neutral today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating EUROFINS SCIENTIFIC stock shows the sell signal. See more of EUROFINS SCIENTIFIC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.